/PRNewswire/ Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced the final results of its Dutch auction.
/PRNewswire/ Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced the final results of its Dutch auction.
Theravance Biopharma, Inc. (NASDAQ:NASDAQ:TBPH) Q3 2022 Earnings Conference Call November 7, 2022 05:00 PM ET Company Participants Rick Winningham – Chairman and Chief Executive Officer.
Reported another record quarter of YUPELRI® (revefenacin) net sales and profitability: $18.7 million Q3 2022 sales up 35% from Q3 2021 (TBPH implied 35%.